Clinical Trial Update: Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Enfortumab Vedotin plus Pembrolizumab for locally advanced or metastatic bladder cancer with variant histology. The trial is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Adenocarcinoma
• Bladder Cancer
• Bladder Squamous Cell Carcinoma
• Unresectable Bladder Cancer
• Urachal Adenocarcinoma

Drugs mentioned

• Keytruda (Pembrolizumab) (pembrolizumab)
• Padcev (enfortumab vedotin) (enfortumab vedotin)

Snippet

Sponsor: Emory University | Conditions: Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Status: RECRUITING